Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

SkinBioTherapeutics (SBTX) Price & Analysis

SBTX Stock Chart & Stats

GBX 5.25GBX 0.00(0.00%)
At close: 4:00 PM EDT
GBX 5GBX 7.5GBX 103 Aug17 Aug1 Sep14 Sep28 Sep12 Oct26 Oct
Day’s Range
GBX 5.00 - GBX 5.50
52-Week Range
GBX 5.00 - GBX 23.00
Previous Close
GBX 5.25
Volume
921.17K
Average Volume (3M)
4.12M
Market Cap
GBP 13.61M
Enterprise Value
GBP 28.27T
Total Cash (Recent Filing)
GBP 3.12M
Total Debt (Recent Filing)
GBP 939.16K
Price to Earnings (P/E)
―
Beta
0.05
Next Earnings
Dec 02, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Sustained double-digit revenue expansion indicates product-market fit and accelerating commercial traction. Over 2-6 months this supports scale economics, strengthens partner bargaining, and provides a foundation to invest in R&D and commercialization even if profitability lags.

Proprietary SkinBiotix Platform

Owning a proprietary skin-microbiome platform creates structural differentiation and IP-driven opportunity. It supports B2B licensing, ingredient supply, and partnership models that can generate recurring revenue and barriers to entry for competitors over the medium term.

Conservative Leverage / Strong Equity Ratio

A low leverage profile and healthy equity ratio give the company financial flexibility to absorb operating losses, fund commercial growth, and pursue partnerships without immediate refinancing pressure, supporting durability through cyclical or cash shortfalls.

Bears Say

Ongoing Unprofitability

Persistent negative net income and EBIT margins reduce internal funding for growth and force reliance on external capital. Without durable margin improvement, profitability risk can limit reinvestment, constrain strategic flexibility, and pressure valuation over multiple quarters.

Negative Operating And Free Cash Flow

Consistently negative operating and free cash flows impair the company's ability to self-fund operations and expansion. Over 2-6 months this raises funding risk, may necessitate dilution or debt, and limits capacity to scale supply or support partners during launch cycles.

High Partner Dependency

Revenue concentration through partner-led commercialization reduces control over go-to-market timing and can create lumpy, volatile revenues. Structural dependence on third-party launches and purchasing decisions increases execution risk and can slow predictable recurring income growth.

SkinBioTherapeutics News

SBTX FAQ

What was SkinBioTherapeutics’s price range in the past 12 months?
SkinBioTherapeutics lowest share price was 5.00 p and its highest was 23.00 p in the past 12 months.
What is SkinBioTherapeutics’s market cap?
SkinBioTherapeutics’s market cap is £13.61M.
When is SkinBioTherapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SkinBioTherapeutics’s earnings last quarter?
SkinBioTherapeutics released its earnings results on Jun 08, 2026. The company reported -0.003 p earnings per share for the quarter.
Is SkinBioTherapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does SkinBioTherapeutics pay dividends?
SkinBioTherapeutics does not currently pay dividends.
What is SkinBioTherapeutics’s EPS estimate?
SkinBioTherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SkinBioTherapeutics have?
SkinBioTherapeutics has 259,168,670 shares outstanding.
What happened to SkinBioTherapeutics’s price movement after its last earnings report?
SkinBioTherapeutics reported an EPS of -0.003 p in its last earnings report. Following the earnings report the stock price went down -17.526%.
Which hedge fund is a major shareholder of SkinBioTherapeutics?
Currently, no hedge funds are holding shares in GB:SBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology